Prevalence of transmitted hiv-1 drug resistance remains low in Guangxi, China, eight years after scale-up of highly-active antiretroviral therapy

Intervirology

Volumn 57, Issue 5, 2014, Pages 270-276

  Li, Guojian ^a   Liang, Shujia ^b   Harrison, Tim J ^c   Tang, Zhenzhu ^b   Shen, Zhiyong ^b   Wang, Xueyan ^b   Wu, Xinghua ^b   Liu, Wei ^b   Liang, Fuxiong ^b   Feng, Liushuai ^b   Yang, Jinye ^b   Fang, Zhongliao ^b  

^a Department of Public Health of Guangxi Zhuang Autonomous Region ^*  (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Epidemiology; Guangxi; Highly active antiretroviral therapy; Human immunodeficiency virus type 1; Transmitted drug resistance

Indexed keywords

DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RILPIVIRINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT; INDINAVIR; POL PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS LOAD; YOUNG ADULT; CHINA; CROSS-SECTIONAL STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; PREVALENCE; SCALE UP; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; PROCEDURES; TRANSMISSION; VERY ELDERLY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHINA; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; YOUNG ADULT;

EID: 84928118950     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000362366     Document Type: Article

References (25)

1. UNAIDS: Report on the Global AIDS Epidemic. Geneva, UNAIDS, 2012. http://relief web.int/report/world/unaids-report-globalaids- epidemic-2012
2. Hemelaar J: The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012; 18: 182-192
3. Karlsson A, Bjorkman P, Bratt G, Ekvall H, Gisslen M, Sonnerborg A, Mild M, Albert J: Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012; 7:e33484
4. Nwobegahay JM, Bessong PO, Masebe TM, Mavhandu LG, Iweriebor BC, Selabe G: Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naive persons visiting a voluntary testing and counselling centre in northeastern South Africa. J Health Popul Nutr 2011; 29: 303-309
5. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S: Global trends in antiretroviral resistance in treatment- naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet 2012; 380: 1250-1258
6. Cortez KJ, Maldarelli F: Clinical management of HIV drug resistance. Viruses 2011; 3: 347-378
7. Readhead AC, Gordon DE, Wang Z, Anderson BJ, Brousseau KS, Kouznetsova MA, Forgione LA, Smith LC, Torian LV: Transmitted antiretroviral drug resistance in New York State, 2006-2008: Results from a new surveillance system. PLoS One 2012; 7:e40533
8. The Ministry of Health of China, UNAIDS, WHO: HIV/AIDS Estimate Process in China in 2007. Chin J AIDS STD 2012; 18: 1-5
9. Liu W, Liang FX, Wang SS, Chen J: The report of the first confirmed Chinese case with HIV in Guangxi. Guangxi Med J 1993; 15: 193-194
10. Chen J, Liang FX, Liang SL, Li RJ, Liu W, Yang JY, Wang SS, Gu YC, He B: An investigation on HIV infection among drug users at Pingxiang City in Guangxi province, Southern China. Chin J AIDS STD 1998; 4: 97-99
11. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(suppl 2):25-36
12. Avila-Rios S, Mejia-Villatoro CR, Garcia- Morales C, Soto-Nava M, Escobar I, Mendizabal R, Giron A, Garcia L, Reyes-Teran G: Prevalence and patterns of HIV transmitted drug resistance in Guatemala. Rev Panam Salud Publica 2011; 30: 641-648
13. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, Van De Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
14. Schellenberg JJ, Plummer FA: The microbiological context of HIV resistance: Vaginal microbiota and mucosal inflammation at the viral point of entry. Int J Inflam 2012; 2012: 131243.
15. Su Q, Liang H, Cen P, Bi Z, Zhou P: HIV type 1 subtypes based on the pol gene and drug resistance mutations among antiretroviral-naive patients from Guangxi, Southern China. AIDS Res Hum Retroviruses 2012; 28: 725-728.
16. Li L, Chen L, Liang S, Liu W, Li T, Liu Y, Li H, Bao Z, Wang X, Li J: Subtype CRF01-AE dominate the sexually transmitted human immunodeficiency virus type 1 epidemic in Guangxi, China. J Med Virol 2013; 85: 388-395.
17. Stadeli KM, Richman DD: Rates of emergence of HIV drug resistance in resource-limited settings: A systematic review. Antivir Ther 2013; 18: 115-123.
18. Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR: The global status of HIV drug resistance: Clinical and publichealth approaches for detection, treatment and prevention. Infect Disord Drug Targets 2011; 11: 124-133.
19. Chen M, Ma Y, Duan S, Xing H, Yao S, Su Y, Luo H, Yang L, Chen H, Fu L, Qu A, Ou CY, Jia M, Lu L: Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: A hot area of viral recombination in China. BMC Infect Dis 2012; 12: 382.
20. Yang C, Liu S, Zhang T, Hou Y, Liu X, Gao Y, Yang G, Wang Z, Chen H, Li M, Zhu Z: Transmitted antiretroviral drug resistance and thumb subdomain polymorphisms among newly HIV type 1 diagnosed patients infected with CRF01-AE and CRF07-BC virus in Guangdong province, China. AIDS Res Hum Retroviruses 2012; 28: 1723-1728.
21. Li L, Sun B, Zeng H, Sun Z, Sun G, Yang R: Relatively high prevalence of drug resistance among antiretroviral-naive patients from Henan, Central China. AIDS Res Hum Retroviruses 2014; 30: 160-164.
22. Ruan Y, Xing H, Wang X, Tang H, Wang Z, Liu H, Su B, Wu J, Li H, Liao L, Li J, Wu JW, Shao Y: Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop Med Int Health 2010; 15: 1357-1363.
23. Xing H, Wang X, Liao L, Ma Y, Su B, Fu J, He J, Chen L, Pan X, Dong Y, Liu W, Hsi JH, Yang L, Ruan Y, Shao Y: Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment. PLoS One 2013; 8:e62408.
24. Aldrich C, Hemelaar J: Global HIV-1 diversity surveillance. Trends Mol Med 2012; 18: 691-694.
25. Hemelaar J: Implications of HIV diversity for the HIV-1 pandemic. J Infect 2013; 66: 391-400.